
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is positioned for substantial growth, with projected revenue increases exceeding 20% annually through 2026, driven primarily by commercial sales ramp-ups of key products and new launches. The company reported a significant rise in total income—$28.5 million in 2024 compared to $4.8 million in 2023—attributed to enhancements in purchased receivables and customer contracts. Furthermore, forecasts for 2026 anticipate revenues reaching $49.0 million, reflecting a 36% increase from the preceding year, bolstered by both commercial-stage assets and potential milestone payments from earlier-stage assets.
Bears say
XOMA Royalty Corp has experienced significant variability in its revenues and net earnings, primarily due to the volatility associated with the international markets for its products, which could lead to adverse impacts on operations amid potential global economic downturns, tariffs, or changes in reimbursement policies. The company's reliance on partnerships and future economic rights from pre-commercial therapeutic candidates may expose it to risks such as failed clinical trials or challenges in securing necessary funding, which could impede its ability to progress drug development. Furthermore, recent declines in share performance following a pandemic-related peak and concerns regarding potential executive departures could amplify operational challenges and negatively affect investor confidence.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares